𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A transgenic mouse model of the slow-channel syndrome

✍ Scribed by Christopher M. Gomez; Bula B. Bhattacharyya; Pierre Charnet; John W. Day; Cesar Labarca; Robert L. Wollmann; Edward H. Lambert


Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
861 KB
Volume
19
Category
Article
ISSN
0148-639X

No coin nor oath required. For personal study only.

✦ Synopsis


To investigate the effect of acetylcholine receptor (AChR) mutations on neuromuscular transmission and to develop a model for the human neuromuscular disease, the slow-channel syndrome, we generated transgenic mice with abnormal AChRs using a 6 subunit with a mutation in the ion channel domain. In three transgenic lines, nerve-evoked end-plate currents and spontaneous miniature end-plate currents (MEPCs) had prolonged decay phases and MEPC amplitudes were reduced by 33%. Single nerve stimuli elicited repetitive compound muscle action potentials in vivo. Transgenic mice were abnormally sensitive to the neuromuscular blocker, curare. These observations demonstrate that we can predictably alter AChR function, synaptic responses, and muscle fiber excitation in vivo by overexpressing subunits containing well-defined mutations. Furthermore these data support the hypothesis that the electrophysiological findings in the neuromuscular disorder, the slow-channel syndrome, are due to mutant AChRs.


πŸ“œ SIMILAR VOLUMES


Transgenic mouse model for the fragile X
✍ Kooy, R. Frank; D'Hooge, Rudi; Reyniers, Edwin; Bakker, Cathy E.; Nagels, Guy; D πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 513 KB

Transgenic fragile X knockout mice have been constructed to provide an animal model to study the physiologic function of the fragile X gene (FMR1) and to gain more insight into the clinical phenotype caused by the absence of the fragile X protein. Initial experiments suggested that the knockout mice

MRI assessment of neuropathology in a tr
✍ Joseph A. Helpern; Sang-Pil Lee; Maria F. Falangola; Victor V. Dyakin; Adam Boga πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 227 KB

## Abstract The cerebral deposition of amyloid β‐peptide, a central event in Alzheimer's disease (AD) pathogenesis, begins several years before the onset of clinical symptoms. Noninvasive detection of AD pathology at this initial stage would facilitate intervention and enhance treatment success. In

Erythropoietin is neuroprotective in a t
✍ Martin KΓΆllensperger; Florian Krismer; Anton Pallua; Nadia Stefanova; Werner Poe πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 441 KB

## Abstract Multiple system atrophy is a rapidly progressive neurodegenerative disorder with a markedly reduced life expectancy. Failure of symptomatic treatment raises an urgent need for disease‐modifying strategies. We have investigated the neuroprotective potential of erythropoietin in (proteoli